Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free HCM Stock Alerts

HUTCHMED (HCM) Competitors

HUTCHMED logo
GBX 184 +2.00 (+1.10%)
As of 08/21/2026 11:55 AM Eastern
Compare

HCM vs. DPH, HIK, INDV, VEC, and ERGO

Should you buy HUTCHMED stock or one of its competitors? HUTCHMED's main competitors and comparable companies include Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), Indivior (INDV), Vectura Group (VEC), and Ergomed (ERGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Dechra Pharmaceuticals?

HUTCHMED (LON:HCM) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

HUTCHMED has a net margin of 163.84% compared to Dechra Pharmaceuticals' net margin of -3.66%. HUTCHMED's return on equity of 36.88% beat Dechra Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 36.88% -5.90%
Dechra Pharmaceuticals -3.66%-3.92%0.75%

Dechra Pharmaceuticals has higher revenue and earnings than HUTCHMED. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M2.91-£52.98M£2.0092.00
Dechra Pharmaceuticals£761.50M0.00-£27.90M-£0.25N/A

In the previous week, HUTCHMED's average media sentiment score of 0.00 equaled Dechra Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
HUTCHMED Neutral
Dechra Pharmaceuticals Neutral

HUTCHMED has a beta of 0.428, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

20.3% of HUTCHMED shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Dechra Pharmaceuticals beats HUTCHMED on 6 of the 10 factors compared between the two stocks.

How does HUTCHMED compare to Hikma Pharmaceuticals?

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
HUTCHMED Neutral
Hikma Pharmaceuticals Positive

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M2.91-£52.98M£2.0092.00
Hikma Pharmaceuticals£3.42B1.00£353.21M£181.009.04

20.3% of HUTCHMED shares are held by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 2.8% of HUTCHMED shares are held by company insiders. Comparatively, 22.0% of Hikma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals has a consensus target price of GBX 2,060, suggesting a potential upside of 25.92%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 11.31%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 36.88% -5.90%
Hikma Pharmaceuticals 11.31%15.05%9.40%

HUTCHMED has a beta of 0.428, indicating that its share price is 57% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.

How does HUTCHMED compare to Indivior?

Indivior (LON:INDV) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

86.0% of Indivior shares are owned by institutional investors. Comparatively, 20.3% of HUTCHMED shares are owned by institutional investors. 3.4% of Indivior shares are owned by insiders. Comparatively, 2.8% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Indivior has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, indicating that its share price is 57% less volatile than the broader market.

In the previous week, Indivior had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for Indivior and 0 mentions for HUTCHMED. Indivior's average media sentiment score of 0.75 beat HUTCHMED's score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company Overall Sentiment
Indivior Positive
HUTCHMED Neutral

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
HUTCHMED£549.12M2.91-£52.98M£2.0092.00

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 11.44%. HUTCHMED's return on equity of 36.88% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior11.44% -23.90% 2.37%
HUTCHMED 163.84%36.88%-5.90%

Summary

Indivior beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Vectura Group?

HUTCHMED (LON:HCM) and Vectura Group (LON:VEC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, HUTCHMED's average media sentiment score of 0.00 equaled Vectura Group'saverage media sentiment score.

Company Overall Sentiment
HUTCHMED Neutral
Vectura Group Neutral

Vectura Group has lower revenue, but higher earnings than HUTCHMED. Vectura Group is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M2.91-£52.98M£2.0092.00
Vectura Group£190.60M0.00N/A£20.10N/A

20.3% of HUTCHMED shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HUTCHMED has a net margin of 163.84% compared to Vectura Group's net margin of 0.00%. HUTCHMED's return on equity of 36.88% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 36.88% -5.90%
Vectura Group N/A N/A N/A

Summary

HUTCHMED beats Vectura Group on 6 of the 8 factors compared between the two stocks.

How does HUTCHMED compare to Ergomed?

Ergomed (LON:ERGO) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Ergomed has higher earnings, but lower revenue than HUTCHMED. Ergomed is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£152.09M0.00£15M£0.29N/A
HUTCHMED£549.12M2.91-£52.98M£2.0092.00

HUTCHMED has a net margin of 163.84% compared to Ergomed's net margin of 9.87%. HUTCHMED's return on equity of 36.88% beat Ergomed's return on equity.

Company Net Margins Return on Equity Return on Assets
Ergomed9.87% 18.08% 10.16%
HUTCHMED 163.84%36.88%-5.90%

Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, suggesting that its stock price is 57% less volatile than the broader market.

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 20.3% of HUTCHMED shares are owned by institutional investors. 18.2% of Ergomed shares are owned by insiders. Comparatively, 2.8% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Ergomed's average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Ergomed Neutral
HUTCHMED Neutral

Summary

Ergomed beats HUTCHMED on 6 of the 10 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

Export
MetricHUTCHMEDPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£1.58B£12.57B£7.37B£2.54B
Dividend Yield4.63%2.61%2.53%6.17%
P/E Ratio92.00789.80272.60367.57
Price / Sales2.91764.53624.3383,481.74
Price / Cash2.4996.7778.6227.89
Price / Book2.1011.8913.057.19
Net Income-£52.98M£2.81B£3.47B£5.89B
7 Day Performance-0.54%1.77%2.09%0.30%
1 Month Performance6.46%3.85%6.64%3.31%
1 Year Performance-23.01%6.56%25.02%22.13%

HUTCHMED Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
N/AGBX 184
+1.1%		N/A-23.0%£1.58B£549.12M92.001,760
DPH
Dechra Pharmaceuticals
N/AN/AN/AN/A£4.40B£761.50MN/A2,457
HIK
Hikma Pharmaceuticals
4.5915 of 5 stars		GBX 1,640
-0.2%		GBX 2,060
+25.6%		-10.9%£3.43B£3.42B9.069,100
INDV
Indivior
N/AGBX 1,238
+1.6%		N/A+0.0%£1.93B£1.40BN/A1,000
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HCM) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel